Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

International Study of Biofield Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03994809
Recruitment Status : Completed
First Posted : June 21, 2019
Last Update Posted : June 21, 2019
Sponsor:
Information provided by (Responsible Party):
Kiyoshi Suzuki, MOA Health Science Foundation

Brief Summary:
Participants from 14 different countries received a single session of biofield therapy (Okada Purifying Therapy) lasting 30 minutes or longer from the volunteer practitioners. Before and after the therapy, they reported the severity of physical pain, anxiety/depression, dizziness/palpitation, and overall symptoms. The team compared the effectiveness/safety of biofield therapy between countries and analyzed the factors associated with the outcomes.

Condition or disease Intervention/treatment
Pain Depression, Anxiety Dizziness Signs and Symptoms Other: Okada Purifying Therapy

Detailed Description:
Participants aged 16 or older from 14 different countries (Japan, USA, Argentina, Brazil, Chile, Mexico, Peru, Taiwan, Thai, South Korea, Belgium, France, Portugal, and Spain) received a single session of biofield therapy (Okada Purifying Therapy) lasting 30 minutes or longer from the volunteer practitioners in their country of residence. Before and after the intervention, they reported each severity level of physical pain, anxiety/depression, dizziness/palpitation, and overall symptoms. The team compared the improvement/exacerbation rate of a single session of biofield therapy between the countries, and examined the adjusted odds ratio of the variables associated with the changes in each category of symptoms in a real-world setting.

Layout table for study information
Study Type : Observational
Actual Enrollment : 12000 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: International Cross-sectional Study on the Effectiveness of Biofield Therapy for the Relief of Various Symptoms
Actual Study Start Date : January 1, 2008
Actual Primary Completion Date : September 30, 2010
Actual Study Completion Date : September 30, 2010

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: Okada Purifying Therapy
    The practitioner raises his/her hand forward towards the recipient with the palm directed toward the recipient. The practitioner uses his/her hands alternately during the administration of Okada Purifying Therapy. The distance between the palm and the body is usually 1-2 feet, with each session typically lasting 30 to 60 minutes.


Primary Outcome Measures :
  1. improvement/exacerbation rate of symptoms after a single session of biofield therapy [ Time Frame: Up to one year after all the data were collected. ]
    The Mann-Whitney test was conducted to compare the improvement/exacerbation rates between countries.

  2. adjusted odds ratio of the factors associated with the changes in symptoms [ Time Frame: Up to one year after all the data were collected. ]
    Logistic regression analyses



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Participants were recruited in various settings, including the workshop, the investigator's house, or the participant's home in 14 different countries.
Criteria

Inclusion Criteria:

  1. Individuals who agreed to receive a single session of biofield therapy for 30 minutes or longer from the volunteer investigators.
  2. Individuals who were able to self-evaluate the change of their symptoms.
  3. Individuals who were competent to answer the questionnaires.
  4. Individuals who were aged 16 or older.

Exclusion Criteria:

  • no specific exclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03994809


Sponsors and Collaborators
MOA Health Science Foundation
Investigators
Layout table for investigator information
Study Chair: Kiyoshi Suzuki, MD, PhD MOA Health Science Foundation
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Kiyoshi Suzuki, President, MOA Health Science Foundation
ClinicalTrials.gov Identifier: NCT03994809    
Other Study ID Numbers: MOA-004
First Posted: June 21, 2019    Key Record Dates
Last Update Posted: June 21, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kiyoshi Suzuki, MOA Health Science Foundation:
biofield therapy
ethnic differences
Okada Purifying Therapy
effectiveness
safety
Additional relevant MeSH terms:
Layout table for MeSH terms
Dizziness
Signs and Symptoms
Sensation Disorders
Neurologic Manifestations